IL17A and ankylosing spondylitis: Recently, anti-TNF therapy was shown to downregulate IL-17 expression and the frequency of Th17 cells in ankylosing spondylitis patients [20]; therefore, we tested whether it was also the case in chronic T. cruzi infection.